Is AstraZeneca a Good Investment in 2026?

Important: This article is for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy, sell, or hold any security. Investing involves risk — you may get back less than you invest. If you are unsure whether an investment is right for you, please consult a qualified financial adviser who is authorised by the Financial Conduct Authority (FCA).

AstraZeneca is the FTSE 100's largest company by market capitalisation. Since Pascal Soriot took the helm in 2012, it has transformed from a patent-cliff casualty into one of the world's most valuable pharmaceutical businesses. After a decade of exceptional returns, many investors are asking whether the opportunity has passed — or whether there is still a case for holding the shares.

This article sets out the key factors investors typically consider when researching AZN, using Openbook's scoring model as a reference point.

The Openbook Scores

Openbook's scoring model analyses publicly available financial data to produce reward and risk scores on a 0–100 scale. These scores are model outputs based on historical data and are not investment recommendations.

| Metric | Score | |---|---| | Reward Rating | 68 / 100 | | Risk Rating | 42 / 100 | | Growth Score | 74 / 100 | | Profitability Score | 61 / 100 |

A higher reward score reflects stronger historical growth, momentum, and profitability metrics. A lower risk score reflects a stronger balance sheet and more stable financials. These scores do not predict future performance.

You can explore AZN's live scores and underlying data on Openbook's AstraZeneca page.

What AstraZeneca Does

AstraZeneca develops and sells prescription medicines across oncology, rare diseases, cardiovascular, and respiratory. Its oncology franchise — built around Tagrisso, Calquence, Enhertu, and Imfinzi — accounts for over 40% of revenue and has been the primary growth engine.

The company is headquartered in Cambridge, UK, listed on the London Stock Exchange (AZN.L) and NASDAQ (AZN), and is a constituent of the FTSE 100.

Factors Commonly Cited in Favour

Pipeline depth. AstraZeneca has over 170 projects in its pipeline, with more than 20 in late-stage trials. Its oncology pipeline includes Enhertu — an antibody-drug conjugate developed with Daiichi Sankyo that has received significant attention from the medical community.

Revenue growth track record. Revenue grew at a compound rate of roughly 18% annually between 2020 and 2025, driven by volume growth in the US, China, and emerging markets rather than acquisitions.

China exposure. Around 12% of revenue comes from China, where AZN has deep hospital relationships and a growing rare disease franchise. Some analysts view this as a structural advantage in a difficult-to-enter market; others view it as a geopolitical risk.

Dividend trajectory. AZN currently pays a dividend of around $3.10 per share, covered approximately twice by earnings. The payout has grown every year since 2020.

Factors Commonly Cited Against

Valuation. At approximately 20x trailing revenue and 30x forward earnings, AZN trades at a significant premium. Investors should consider what level of growth is already priced into the shares and what happens if that growth does not materialise.

Patent cliff risk. Tagrisso, AZN's largest single drug at approximately $5.8bn revenue in 2025, faces biosimilar competition from the late 2020s. Management has indicated pipeline successors, but transitions of this scale carry execution risk.

Currency headwinds. With most revenue denominated in USD and a UK-listed primary share price, sterling appreciation compresses GBP-translated reported earnings.

Execution risk in emerging markets. Growth ambitions in Brazil, India, and Southeast Asia bring pricing pressure, regulatory complexity, and slower reimbursement cycles.

Key Questions Investors Typically Research

Before reaching any conclusion about AZN, investors typically consider:

• Is the current valuation justified by the pipeline, or does it price in too much optimism?
• How quickly could biosimilar competition affect Tagrisso revenues?
• How exposed is the business to a deterioration in US-China trade relations?
• How does AZN compare to peers such as GSK (GSK.L) on a risk-adjusted basis?

These are questions each investor must weigh based on their own circumstances, investment horizon, and risk tolerance. Openbook's tools can help with the data — but the decision is yours.

Explore AZN's full financial data on Openbook →

This article is produced for educational purposes only and does not constitute a financial promotion, investment advice, or a personal recommendation. Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invest. AstraZeneca scores shown are model outputs based on historical financial data and are not forward-looking predictions. Openbook Analytics is not authorised by the Financial Conduct Authority to provide investment advice.